The Cost Of Stem Cell Therapy And Why It’s So Expensive …
By Dr. Matthew Watson
How much is stem cell therapy? As stated by CBC Canada,the cost of stem cell therapy is $5,000 to $8,000per stem cell treatment for patients. According to a Twitter poll by BioInformant, the cost can be even higher. Our May 2018 poll found that stem cell treatments can cost as much as $25,000 or more. This article explores the key factors that impact the cost of stem cell therapy, including the type of stem cells used within the protocol, the number of treatments required, and the site of theclinic. It also provides pricing quotes from stem cell clinics within the U.S. and worldwide.
In this article:
Stem cell therapy is the use of living cells as therapeutics to treat disease or injury. Read on to learn about the cost requirements of these procedures.
CBC Canadas pricing involves Cell Surgical Network (CSN) following its protocol to remove fat tissue and process it before re-injecting [adipose-derived stem cells] either directly or intravenously into the same patient. Unfortunately, the U.S. FDA and Department of Justice (DOJ) sent this network of stem cell treatment providers a permanent injunction notice in May 2018. Therefore, patients should not seek treatments from the group at this time.Although Cell Surgical Network (CSN) is based in California, it has a network of approximately 100 U.S. treatment centers. They also have three Canadian clinics located in Vancouver, Sudbury,andKamloops.
The controversy such as the one above stirs up questions about the safety of stem cell procedures. Anyone considering stem cell therapy from any tissue or source will benefit from understanding the possible consequences of stem cell therapy and the factors driving costs.
For the patient, a stem cell transplant involves multiple steps, including:
There are also real costs for the doctors who provide stem cell treatments. They have overhead costs, including:
There is also time and expertise required toperform the procedure and offer post-operative care. In some cases, the physician must pay licensing fees to access stem cell sourcing, processing, or delivery technologies.
Stem cell treatment has gained more and more traction over the last decade. It has been helped along by considerable advances in research. In 2017, the number of scientific publications about stem cells surpassed 300,000. The number of stem cell clinical trials has also surpassed4,600 worldwide.
However, stem cell therapy is still expensive. Among the cheapest and easiest options is to harvest adipose-derived stem cells (ADSCs) those that exist in adult fat layers and re-deliver them to the patient. Unlike harvesting from bone marrow or teeth, providers can feasibly remove fat, separate stem cells, then re-inject them into a patient the same day. This approach is typically less expensive than those that require more invasive procedures for harvesting. Because of its practicality in terms of cost, it has become a common approach to stem cell treatment.
Relatively easy harvesting stilldoesnt translate to inexpensive cost, although some are certainly more affordable than others. For orthopedic conditions, the costof stem cell therapy is typically lower, averaging between $5,000 and $8,000. Examples of these types of medical conditions include:
Note that these prices are typically out-of-pocket costs paid by the patientbecause most insurance companies will not cover them. They are considered experimental and unapproved by the FDA. This means patients needing stem cell treatment will need to use their own savings.
Although fat is a frequently utilized source for stem cells, it is also possible for physicians to utilize stem cells from bone marrow. Regenexx provides this service in the U.S. and Cayman Islands. With theRegenexxstem cell injection procedure, a small bone marrow sample is extracted through a needle, and blood is drawn from a vein in the arm. These samples are processed in a laboratory, and the cells it contains are injected into an area of the body that needs repair. On June 19, 2018, ACAP Health, a leading provider in innovative, clinical-based solutions partnered with Regenexx to reduce high-cost musculoskeletal surgeries.ACAP Health is a national leader in employer healthcare expense reduction. It is one of the first healthcare groups to partner with a stem cell treatment group to support insurance coverage to patients.
A recent Twitter poll conducted by BioInformant reported that, on average, patients can expect to spend $25,000 or more on stem cell therapies. According to the poll,
Most likely, those paying lower stem cell treatment costs under $5,000 were pursuing treatment for orthopedic or musculoskeletal conditions. In contrast, those paying higher treatment costs were likely getting treated for systemic or more complex conditions, such as diabetes, multiple sclerosis (MS), neurodegenerative diseases (such as Alzheimers disease or dementia), psoriatic arthritis, as well as the treatment for autism.
In the U.S., treatment protocols vary depending on the clinic and the treating physician. A one-time treatment that utilizes blood drawn from a patient can cost as little as $1,500. However, protocols that utilize a bone marrow or adipose (fat) tissue extraction can run as much as $15,000 $30,000. This is because bone marrow extraction is an invasive procedure that requires a penetrating bone and adipose tissue extraction requires a medical professional trained in liposuction.
For treatments that require a systemic or whole-body approach, the cost tends to be in the higher range, often averaging from $20,000 to $30,000. Examples of the diseases or conditions requiring this type of stem cell treatment include:
These higher costs reflect the complexity of treating these patients and the fact that multiple treatments are often required.
Founded by Dr. Neil Riordan, a globally recognized stem cell expert, theStem Cell Institutein Panama is one of the worlds most trusted adult stem cell therapy centers. Over the past 12 years, the center has performed more than10,000 procedures, making it a widely recognized destination for stem cell treatments.
Working in collaboration with universities and physicians worldwide, its stem cell treatment protocols utilize combinations of allogeneic human umbilical cord blood stem cells and autologous bone marrow stem cells to treat a wide variety of conditions.
A reader of BioInformant was recently treated for psoriatic arthritis at the Stem Cell Institute in Panama in early 2018. The price of his stem cell treatment was $22,000. With travel and lodging included, the total expenses were approximately $30,000.
Because of its proximity to the U.S., Mexico is increasingly becoming a destination for medical tourism.Before choosing a stem cell treatment provider in Mexico, ensure the clinic is fully authorized by COFEPRIS, the Mexican equivalent to the FDA.
One patient who recently shared stem cell treatment quotes with BioInformant found that the treatment for glycogen storage disease, a metabolic disorder that often onsets in infancy and continues into adulthood, would cost $23,900 throughGIOSTAR Mexico.
In contrast, the patient was quoted$33,000 throughCelltex, a U.S.-based company that treats patients in Cancun, Mexico.Celltex follows FDA regulations concerning the export of cells to Mexico and is compliant with the standards and procedures of COFEPRIS. Celltex also has an alliance with a certified hospital in Mexico, which is approved to receive cells and administer them to patients by a licensed physician.
In contrast, the patient was quoted $10,000 from Stem Cell Therapy of Las Vegas and Med Spa, an American clinic. This price difference may reflect regulatory restrictions that prevent U.S. providers from expanding cells. It may also reflect the therapeutic approach used by the clinic, as well as the quality of their expertise.
In Mexico, where certain types of stem cell expansion are allowed that are restricted within the U.S., treatment protocols vary depending on the clinic and the treating physician. A one-time treatment that utilizes peripheral blood from a patient can cost as little as $1,000. In contrast, protocols that utilize more invasive sources of stem cells can run as much as $15,000 $35,000. Examples of invasive procedures includebone marrow and adipose tissue extraction. In some cases, hospitalization may be required, which raises costs. The location of a stem cell facility can factor heavily into thecost of the procedure.
Not every cost associated with treatment gets billed to the patient at the time of the procedure. Hidden costs such as reactions to the treatment, graft-versus-host disease, or disability derived from the treatment can all result in more money to the patient, to insurance, or to the government.
For example, in the case of someone with cancer, it frequently isnt viable to harvest the patients own stem cells because they may contain cancerous cells that can reintroduce tumors to the body. Instead, the patient would receive stem cells by transplant. Treatments that involve cells from another person are called allogeneic treatments. The danger here is that the body may see those cells as invaders and attack them via the immune system, a condition known as graft-versus-host disease (GvHD). The body (host) and the introduced stem cells (graft) then battle rather than coexist.
Transplanted cells often face the risk of being rejected by their host; this article discusses the effect of plasma exchange on acute graft vs. host diseasehttps://t.co/cA3nzFntew
Katie Bunde (@kbuns76) May 29, 2018
In addition to making the stem cell treatments less effective or ineffective, GvHD can be deadly. Roughly30 to 60 percent ofhematopoieticstem cell and bone marrow transplantationpatients sufferfrom it, and of those, 50 percent eventually die. The hospital costs associated with it are substantial.
Another hidden cost is the potential to disrupt a system that formerly functioned adequately. The best current example of this isthe case of Doris Tyler, who received bilateral stem cell injections in her eyes from Drs.RobertHalpernand JamieWalraven of Stem Cell Center of Georgia. According to her, while her vision was failing, it was still good enough to perform various tasks, and now it is not. That means the cost increases for her, as well as potential insurance or disability claims (though again, insurance is unlikely to cover the specific consequences of this action).
Because of tight regulations surrounding stem cell procedures performed in the United States, many stem cell treatment providers provide both on-shore (U.S.-based) and offshore (international) treatment options.Depending on where a treatment is received, patients may have to pay travel, lodging,and miscellaneous expenditures.
For example, Regenexx offers treatments at a wide range of U.S. facilities using non-expanded stem cells. However, it also offers a laboratory-expanded treatment option at a site in the Cayman Islands, which can administer higher cell doses to patients by expanding the cells in culture within a laboratory.
Similarly, Okyanos (pronounced Oh key AH nos) offers treatments to patients at its Florida location and provides more involved stem cell procedures at its offshore site inGrand Bahama. It was founded in 2011 and is a stem cell therapy provider specializing in treatments for congestive heart failure (CHF) and other chronic conditions. It is fully licensed under the Bahamas Stem Cell Therapy and Research Act and adheres to U.S. surgical center standards.
Similarly, Celltex is headquartered in Houston, Texas, but offers stem cell treatments in Cancun, Mexico. Celltex specializes in storing a patients mesenchymal stem cells (MSCs) for therapeutic use.
While no hard evidence yet points to stem cell clinics raising their rates as a result of lawsuits, that is a typical response in industries whose products or services the public perceives as a high risk.
An additional danger to stem cell treatment providers,points out Nature, is the reduction of bottom-line profits through former patients winning suits. If clinics have to pay out the money they earned and then some to individuals suing for damages, they may soon become faced with an unviable business model. That is a definite concern for those hoping to leverage these treatments now and in the future.
As with any other area of medicine, patient evaluations of stem cell providers and treatments run the gamut from extremely satisfied to desolately unhappy. Those like Doris Tyler who have lost their eyesight exist at the negative end of the spectrum. However, many others praise stem cell treatments for their power to heal diseases, boost immunity, fight cancer, and more.
For example, BioInformants Founder and President, Cade Hildreth, had a favorable experience with stem cell therapy. Cade had bone marrow-derived stem cells collected and then had them re-injected into the knee to treat a devastating orthopedic injury. Cade was able to reverse pain, swelling, and scarring to reclaim an elite athletic ability.
As of now, this much is clear. There exists enough interest in America and across the world that stem cell providers are continuing to offer a wide range of treatments. Stem cell treatments also offer the potential to reverse diseases that traditionally had to be chronically managed by drugs. Like most medical practices, stem cell treatments will require further testing to reveal merits and faults. Until then, the public will likely continue to pursue services when medical needs arise.
Although the cost of stem cell therapy is pricey, some patients choose to undergo the treatment because it is more economical than enduring the costs associated with chronic diseases.
Although most stem cell therapy providers do not provide FDA-approved procedures, the Food and Drug Administration (FDA) continues to encouragepatients to pursue approved therapies, even if there is a higher associated treatment cost.
Providers rarely post their prices for stem cell treatments in print or digital media because they want patients to understand the benefits of therapy before making a price decision. Additionally, the price of stem cell treatments varies by condition, the number of treatments required, and the complexity of the procedure, factors that can make it difficult for medical providers to provide cost estimates without a diagnostic visit for the patient. However, in many cases, it is not in the patients best interest to make treatment decisions based on the cost of stem cell therapy. The best way to know whether to pursue stem cell therapy is to explore patient outcomes by condition and compare the healing process to other surgical and non-surgical treatment options.
The cost of stem cell therapy is indeed expensive, especially because the procedures are rarely covered by health insurance. However, with the right knowledge and a clear understanding of the treatment process, the risk of undergoing stem cell therapy can be worth it, especially if it removes the requirement for a lifetime of prescription medication. Although stem cell therapy has associated risks, it has improved thousands of lives and will continue to play in a key role in the future of modern medicine.
Download this infographic for your reference:
Are you seeking a stem cell treatment? If so, we have partnered with GIOSTAR to help you acccess medical guidance and advice.
In alignment with what we believe at BioInformant, GIOSTARs goal is to offer cutting-edge, extensively researched stem cell therapy options designed to rejuvenate and improve a patients quality of life.
Click here to Schedule a Consultation or ask GIOSTAR a question.
If you found this blog valuable, subscribe to BioInformants stem cell industry updates.
As the first and only market research firm to specialize in the stem cell industry, BioInformant research is cited by The Wall Street Journal, Xconomy, AABB, and Vogue Magazine. Bringing you breaking news on an ongoing basis, we encourage you to join more than half a million loyal readers, including physicians, scientists, executives, and investors.
Do you think the cost of stem cell therapy is too much? Share your thoughts in the comments section below.
Up Next: Japan to Supply Human Embryonic Stem Cells (hESC) for Clinical Research
Cost Of Stem Cell Therapy And Why Its So Expensive
View post:
The Cost Of Stem Cell Therapy And Why It's So Expensive ...
- Induction of muscle-regenerative multipotent stem cells from human adipocytes by PDGF-AB and 5-azacytidine - Science Advances - January 14th, 2021
- A Potential Therapy for One of the Leading Causes of Heart Disease - PRNewswire - December 10th, 2020
- Evotec and Sartorius Partner with Start-Up Curexsys on IPSC-Based Therapeutic Exosome Approach - BioSpace - December 9th, 2020
- Induced Pluripotent Stem Cell (iPS Cell) Applications in 2020 - November 28th, 2020
- Induced Pluripotent Stem Cell - an overview ... - November 28th, 2020
- The Stem Cell-Derived Cells market to Scale new heights in the next decade - Khabar South Asia - November 28th, 2020
- Stem Cells Market 2020: Rising with Immense Development Trends across the Globe by 2027 - The Market Feed - November 25th, 2020
- The Stem Cell-Derived Cells Market to witness explicit growth from 2019 and 2029 - The Haitian-Caribbean News Network - November 23rd, 2020
- Stem Cells Market Research Provides an In-Depth Analysis on the Future Growth Prospects and Industry Trends Adopted by the Competitors | (2020-2027),... - November 23rd, 2020
- The Stem Cell-Derived Cells market to go the astute way from 2019 to 2029 - TechnoWeekly - November 3rd, 2020
- Global Stem Cells Market 2020 Industry Demand, Share, Global Trend, Top Key Players Update, Business Statistics And Research Methodology By Forecast... - November 3rd, 2020
- Regenerative Medicine in Cosmetic Dermatology | MDedge ... - October 30th, 2020
- G-CON Manufacturing Honored with the Korea Bioprocessing Excellence Award - PR Web - October 30th, 2020
- The Stem Cell-Derived Cells market to be in conjunction to growth from 2020 to 2030 - PRnews Leader - October 29th, 2020
- Harnessing regeneration of retinal tissues: An option almost within reach - Ophthalmology Times - October 23rd, 2020
- Regeneron, Trump, and the alleged hypocrisy of the pro-life movement - Christian Post - October 16th, 2020
- Stem Cell-Derived Cells Market Forecasted To Surpass The Value Of US$ XX Mn/Bn By 2019 - 2029 - Stock Market Funda - October 2nd, 2020
- Ghosh Addresses Brentuximab Vedotin Use in Advanced Hodgkin Lymphoma - Targeted Oncology - September 29th, 2020
- Researchers ID Role of Protein in Development of New Hearing Hair Cells - labmanager.com - September 22nd, 2020
- Convergence: EMA close to finalizing guidance for advanced therapies - Regulatory Focus - September 18th, 2020
- Stem Cells Market Report, History and Forecast 2020-2027, Data Breakdown by Manufacturers, Key Regions, Types and Application - News Degree - September 12th, 2020
- Innovative treatments for heart failure - Open Access Government - September 9th, 2020
- Japan Approves iPS Cell Therapy Trial for Spinal Cord ... - September 7th, 2020
- Optimized Freezing Solutions for Clinical Application of Cell Therapy Products - Technology Networks - September 3rd, 2020
- Stem Cell-Derived Cells Market Forecast to 2025: Global Industry Analysis by Top Players, Types, Key Regions and Applications - The Scarlet - August 30th, 2020
- Cell Therapy Processing Market is Booming Worldwide to Show Significant Growth by 2026 Cell Therapies Pty Ltd,Invitrx Inc.,Lonza Ltd,Merck & Co.,... - August 22nd, 2020
- On the move at the OneAZ, Spencer Fane, UArizona - AZ Big Media - August 20th, 2020
- Increasing Number of iPS Cell Therapies Tested in Clinical ... - August 17th, 2020
- Stem Cell-Derived Cells Market Forecasted To Surpass The Value Of US$ XX Mn/Bn By 2019 2029 - Owned - August 16th, 2020
- Opportunities in the Global Induced Pluripotent Stem Cell (iPS Cell) Industry - PRNewswire - August 11th, 2020
- Stem Cell-Derived Cells Market is Projected to Reach US$XX by the end of 2019 2029 - 3rd Watch News - July 10th, 2020
- Research and therapy with induced pluripotent stem cells ... - July 8th, 2020
- Hitachi and ThinkCyte to Develop an AI-driven Cell Analysis | ARC Advisory - ARC Viewpoints - July 6th, 2020
- Hitachi and ThinkCyte announce collaboration to develop an AI-driven cell analysis and sorting system - BioSpace - July 1st, 2020
- Global Stem Cells Market 2019 | How The Industry Will Witness Substantial Growth In The Upcoming Years | Exclusive Report By MRE - Cole of Duty - June 26th, 2020
- Induced Pluripotent Stem Cells (iPS) - UCLA Broad Stem ... - June 23rd, 2020
- Global Stem Cell Therapy Market 2020: Size, Share, Growth Rate, Revenue and Volume, Key-Players, Top Regions and Forecast Till 2025 - Cole of Duty - June 23rd, 2020
- Global Regenerative Medicine Market (2020 to 2024) - Size & Forecast with Impact Analysis of COVID-19 - ResearchAndMarkets.com - Business Wire - June 18th, 2020
- Vowing to never go back, Ex-con seeks to improve intolerable conditions in Israeli jails - Haaretz - June 8th, 2020
- Excellent growth of Human Embryonic Stem Cells Market- Comprehensive study by key players: Astellas Pharma Inc/ Ocata Therapeutics, Stemcell... - June 4th, 2020
- Global Stem Cell Partnering Deals Collection (2010-2020): Access to Headline, Upfront, Milestone and Royalty Data - PRNewswire - May 18th, 2020
- AgeX Therapeutics Reports First Quarter 2020 Financial Results and Provides Business Update - Insurance News Net - May 18th, 2020
- Global Stem Cell Partnering Terms and Agreements 2010-2020 - ResearchAndMarkets.com - Business Wire - May 18th, 2020
- AgeX Therapeutics Reports First Quarter 2020 Financial Results and Provides Business Update - Business Wire - May 15th, 2020
- Cell and Gene Therapy Catapult links with Japan's CiRA Foundation - PharmaTimes - May 13th, 2020
- Induced Pluripotent Stem Cell (iPSC) Media and Reagents ... - April 27th, 2020
- Evotec Regains Global Rights to Beta Cell Replacement Therapy - Yahoo Finance - April 22nd, 2020
- FDA Approves Tukysa to Treat Advanced or Metastatic HER2-Positive Breast Cancer - Curetoday.com - April 18th, 2020
- Researchers restore sight in mice by turning skin cells into light-sensing eye cells - National Institutes of Health - April 15th, 2020
- Chimeric Antigen Receptor (CAR) T-Cell Therapy Market 2020: Professional Survey & Competitive Dynamics Mustang Bio Inc., iCell Gene Therapeutics,... - April 12th, 2020
- Evotec Expands its iPSC-Based Cell Therapy Platform EVOcells Through Licensing Agreement with panCELLa | More News | News Channels -... - April 6th, 2020
- Evotec partners with panCELLa to enhance cell therapy plaform - ITResearchBrief.com - April 6th, 2020
- Evotec Expands its iPSC-Based Cell Therapy Platform EVOcells Through Licensing Agreement with panCELLa - BioSpace - April 2nd, 2020
- Optimizing the Production of AAV in Sf9 Insect Cells - Technology Networks - April 2nd, 2020
- The Progress & Ongoing Challenge of 3D Bioprinting Cardiac Tissue - 3DPrint.com - March 24th, 2020
- Stem Cell-Derived Cells Value Projected to Expand by 2019-2025 - 3rd Watch News - March 20th, 2020
- Looking to the future with Dr. Francis Collins - Newswise - March 17th, 2020
- Global induced pluripotent stem cells market is expected to grow with a CAGR of 8.6% over the forecast period from 2019-2025 - GlobeNewswire - March 13th, 2020
- Why are Pluripotent Stem Cells Important? Boston ... - March 12th, 2020
- Eye health: Testing the safety of stem cell therapy for age-related macular degeneration - Open Access Government - March 10th, 2020
- AgeX Therapeutics Researchers Publish Paper on the Age Reprogramming of Super-Centenarian Cells - Yahoo Finance - February 29th, 2020
- CAR T-Cell Therapy: Genetically Programming the Immune System to Attack Malignant Cells - Pharmacy Times - February 25th, 2020
- Stem Cell Therapy Contract Manufacturing Industry, 2019-2030 - Availability of Cutting-Edge Tools & Technologies has Emerged as a Differentiating... - February 17th, 2020
- Surge in the Adoption of Stem Cell-Derived Cells to Fuel the Growth of the Stem Cell-Derived Cells Market Through the Assessment Period 2019 2029 -... - February 17th, 2020
- NIH launches first U.S. clinical trial of patient-derived ... - February 4th, 2020
- Update on stem cell treatment cost for 2018 from ongoing ... - February 4th, 2020
- Team based at Osaka University carries out world's first transplant of heart cells generated from iPS cells - Medical Herald - January 31st, 2020
- Osaka University-based team successfully conducts first transplantation of cardiac muscle cells around the globe - Medical Herald - January 30th, 2020
- Osaka University transplants iPS cell-based heart cells in world's first clinical trial - The Japan Times - January 27th, 2020
- Kyoto University team gets OK from ministry for plan to transplant iPS-derived cartilage into knee joints - The Japan Times - January 25th, 2020
- The Kyoto University team's plan to transplant iPS cartilage into knee joints is OK - gotech daily - January 25th, 2020
- Psychiatric body condemns use of stem cell therapies to treat psychiatric disorders - Moneycontrol.com - January 20th, 2020
- Allele and Astellas Enter into an Expanded License for the Development of iPSC Lines - Business Wire - January 19th, 2020
- Cell Therapy And Tissue Engineering Market Size 2020 by Top Leading Companies- BioCardia Betalin Therapeutics, MEDIPOST Co., MaxCyte BioReliance... - January 16th, 2020
- Allele and Astellas Enter into an Expanded License for the Development of iPSC Lines - BioSpace - January 16th, 2020
- Where Are They Now? Top 3 Biotech Startups From NextGen Bio Class of 2018 - BioSpace - January 7th, 2020
- Global Stem Cell Therapy Market to Surpass US$ 40.3 Billion by 2027 Coherent Market Insights - Business Wire - December 18th, 2019
- Stem Cell-Derived Cells Market To Boost Demand And Forecast In Upcoming Year 2019 2029 - Downey Magazine - December 16th, 2019
- AgeX Therapeutics and Lineage Cell Therapeutics Announce Issuance of US Patent for Method of Generating Induced Pluripotent Stem Cells - Press Release... - December 15th, 2019
- Stem Cell-Derived Cells Market Expected to Expand at a Steady CAGR through 2019 2029 - Downey Magazine - December 15th, 2019
